Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Relief to Lupin: High...

    Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-02-23T12:57:29+05:30  |  Updated On 2021-08-16T15:29:09+05:30

    The high court has now ruled in favour of Lupin and quashed the apex court's decision to ban Lupin's anti-diabetic drug- Gluconorm P 30.


    New Delhi: In a major relief to the Mumbai-based drugmaker, Lupin Limited, the Delhi high court has set aside a central government notification in which it had banned the manufacture, sale and distribution of the company's fixed-dose combination (FDC) Gluconorm P 30, an anti-diabetic drug.


    Gluconorm P 30, is a combination of Pioglitazone 30 and Metformin 500. The combo drug is used to minimize the individual dose requirement of diabetes sufferer. It is used to regulate high blood sugar levels in patients with type-2 diabetes.

    Medical Dialogues had earlier reported that the Ministry of Health and Family Welfare had prohibited the manufacture for sale, sale or distribution for human use of 328 Fixed Dose Combinations (FDCs).


    The move came after the DTAB recommended that there was no therapeutic justification for the ingredients contained in 328 FDCs and that these FDCs might involve risk to human beings. Earlier, an expert committee appointed by the Centre had also made similar observations.


    Also Read: Health Minsitry bans 328 FDC Banned Drugs, check out the complete list


    The move was challenged by the affected manufacturers including Unison Pharmaceuticals Pvt Ltd, Alkem Laboratories Ltd, East West Pharma, Intas Pharmaceuticals Ltd, Lupin Ltd, Micro Labs Ltd, Eris Lifesciences Ltd and Franco Indian Pharmaceuticals.


    However, the Delhi High Court had rejected a batch of pleas challenging the Centre's notification banning manufacture and sale of fixed dose combination (FDC) drugs used for the treatment of Type-II diabetes.


    Justice Vibhu Bakhru said there was no ground to interfere with the central government's September 7, 2018, notification and dismissed the petitions filed by eight pharma companies.


    Also Read: No relief for Fixed Dose Combinations in Type 2 Diabetes: HC rejects pharma plea


    The High court has now ruled in favour of Lupin and quashed the apex court's decision to ban Lupin's anti-diabetic drug- Gluconorm P 30.


    Diabetes mellitus type 2 (or adult-onset diabetes) is a metabolic disorder where high levels of blood sugar occur. Left untreated, it can cause heart attacks, strokes, blindness and kidney failure.


    Commenting on the matter the counsel for the company, Ajay Bhargava told Business Standard, "In addition to lowering blood sugar, the dual drug can effectively reduce the use of insulin in patients suffering from type 2 diabetes. Thus, Lupin had challenged the ban imposed by the central government."


    Gluconorm P 30 is the second anti-diabetes drug, manufactured by Lupin, which has been taken out of the banned FDC list adds BS. The high court had on January 13 set aside another notification vide which the government had banned Lupin's anti-diabetic drug Gluconorm -PG 1 Forte and Gluconorm -PG 2 Forte.

    apex court blood glucose center;s ban Delhi Delhi high court diabetes drug diabetes type 2 FDC Fixed Dose Combination fixed dose combinations GLUCONORM Gluconorm P30 government ban Lupin lupin diabetes drugs Ministry of Health and Family Welfare Pioglitazone 30+metformin 500 Supreme Court type-2 diabetes 
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Lupin gets USFDA EIR for Nagpur Facility

      Lupin gets USFDA EIR for Nagpur Facility

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by manufacturers

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by...

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X